Bladder cancer is the most common cancer of the urinary tract with ~380,000 new cases and ~150,000 deaths per year worldwide 1 . It ranks fifth among cancers in men in Western countries. Epidemiological studies identify a range of environmental risk factors, many of which reflect exposure to excreted carcinogenic molecules (BOX 1). Recent genome-wide association studies have also identified germline variants that contribute to risk 2 . In Europe and North America, >90% of bladder cancers are urothelial carcinoma. These tumours are staged using the Tumour-Node-Metastasis system (TNM system) 3 , which describes the extent of invasion (Tis-T4), and they are graded according to their cellular characteristics. Two classification systems are in current use 4, 5 . At diagnosis the majority of bladder cancers (~60%) are non-muscleinvasive (stage Ta) papillary tumours of low grade (FIG. 1) . Stage T1 tumours, which have penetrated the epithelial basement membrane but have not invaded the muscle, are mostly of high grade, as are muscle-invasive bladder cancers (MIBCs; ~20% at diagnosis).
. In Europe and North America, >90% of bladder cancers are urothelial carcinoma. These tumours are staged using the Tumour-Node-Metastasis system (TNM system) 3 , which describes the extent of invasion (Tis-T4), and they are graded according to their cellular characteristics. Two classification systems are in current use 4, 5 . At diagnosis the majority of bladder cancers (~60%) are non-muscleinvasive (stage Ta) papillary tumours of low grade (FIG. 1) . Stage T1 tumours, which have penetrated the epithelial basement membrane but have not invaded the muscle, are mostly of high grade, as are muscle-invasive bladder cancers (MIBCs; ~20% at diagnosis).
Non-muscle-invasive bladder cancers (NMIBCs) frequently recur (50-70%) but infrequently progress to invasion (10-15%) 6 , and five-year survival is ~90%. These patients are monitored by cystoscopy and may have multiple resections over many years. Improved monitoring is needed, ideally via urine analysis, which could reduce the morbidity and costs associated with cystoscopy. Although risk tables provide a prognostic tool 7 , no molecular biomarkers accurately predict disease progression. For these patients, localized therapies to remove residual neoplastic and pre-neoplastic cells post-resection may have major impacts both on quality of life and in health economic terms. MIBCs (of stage T2 and above) have less favourable prognosis with five-year survival <50% and common progression to metastasis
. Treatment has not advanced for several decades, and new approaches to systemic therapy are needed 8 . Improved treatment requires detailed understanding of urothelial carcinoma pathogenesis and molecular biology. A model has evolved, taking into account both histopathological and molecular features. This 'two-pathway' model proposes that papillary NMIBC develops via epithelial hyperplasia and recruitment of a branching vasculature. MIBC is proposed to develop via flat dysplasia and carcinoma in situ (CIS). The molecular characteristics of MIBC and NMIBC are highly distinct (TABLES 1, 2) . While many features of bladder cancer fit well within this model, there is considerable heterogeneity in clinical behaviour. This Review discusses the molecular features of bladder tumours and recent findings that begin to unravel this heterogeneity and pave the way for a step change in personalized patient care.
Chromothripsis
Chromosomal shattering. A phenomenon whereby cancer cells acquire many clustered chromosomal rearrangements as a single catastrophic event during tumour development.
Non-homologous end-joining
An error-prone mechanism of DNA repair in which broken DNA ends are joined without the guidance of a large homologous template. Short homologous DNA sequences termed microhomologies are used to guide repair.
Replication-licensing complex
A complex of proteins that assemble at origins of DNA replication during late G1 phase of the cell cycle to ensure precise and timely DNA replication.
Homologous recombination
A high-fidelity mechanism of DNA repair that uses recombination with an intact homologous template to repair double-strand breaks.
Bacillus Calmette-Guerin (BCG) . A vaccine used to induce immunity to tuberculosis. It is also used to treat high-risk localized bladder cancer and carcinoma in situ. Instillation of BCG into the bladder induces a localized immune response that is able to eliminate cancer cells. For bladder cancer treatment, a course of 6 weekly treatments is usual.
including chromothripsis 9 . Non-homologous end-joining is implicated as a mechanism for error-prone doublestrand break repair in MIBC 9, 10 . The identification of mutations in minichromosome maintenance complex component 4 (MCM4), a component of the replicationlicensing complex, in some MIBCs has led to the suggestion that failure to rescue stalled replication forks may underlie complex translocation events involving multiple chromosomes 9 . Inactivating mutations are reported in DNA repair and DNA damage checkpoint genes, including excision repair cross-complementation group 2 (ERCC2), ataxia-telangiectasia mutated (ATM) and Fanconi anaemia complementation group A (FANCA) in MIBC. Frequent mutation of stromal antigen 2 (STAG2), which encodes a component of the cohesin complex, has been identified, and this mutation occurs with higher frequency in NMIBC than in MIBC [11] [12] [13] . Cohesin plays a part in chromatid segregation and, in other tumour types, STAG2 inactivation is associated with aneuploidy 14 . In bladder cancer there is no clear relationship to aneu ploidy 11, 13 . As cohesin also plays a part in genomic organization via interaction with CCCTC-binding factor (CTCF) 15 and in DNA double-strand break repair by homologous recombination 16 , these functions may be more important than effects on ploidy. Several other genes involved in sister chromatid cohesion and segregation -STAG1, nipped-B homologue (NIPBL), structural maintenance of chromosomes 1A (SMC1A), SMC1B, SMC3 and extra spindle pole bodies homologue 1 (ESPL1) -show mutation in MIBC 11, 17 . Such defects lead to a variety of chromosomal alterations. Chromosome 9 deletion is common in both NMIBC and MIBC (>50%). Candidate tumour suppressor genes affected by chromosome 9 deletion are cyclin-dependent kinase inhibitor 2A (CDKN2A; which encodes p16 and p14 ARF ) and CDKN2B (which encodes p15) at 9p21 (REFS 18, 19) ; patched 1 (PTCH1) at 9q22 (REFS 20, 21) ; deleted in bladder cancer 1 (DBC1; also known as BRINP1) at 9q32-33 (REFS 22, 23) ; and tuberous sclerosis 1 (TSC1) at 9q34 (REFS 24, 25) . Loss of heterozygosity (LOH) of 9p, homozygous deletion of CDKN2A and loss of expression of p16 in NMIBC are predictors of reduced recurrence-free interval [26] [27] [28] . As mouse knockouts and in vitro experiments 29, 30 suggest that p16 and/or p14 ARF are haploinsufficient tumour suppressors, it is plausible that the loss of one allele in ~45% of bladder cancers has functional consequences. Importantly, in the small group of MIBC with fibroblast growth factor receptor 3 (FGFR3) mutation (discussed below), a high frequency of CDKN2A homozygous deletion has been reported 31 . This may identify a progression pathway for FGFR3-mutant NMIBC to muscle invasion. Loss of p16 expression is inversely correlated with RB1 expression 32 and, conversely, high-level expression results from negative
Box 1 | Key features of bladder cancer
Age is the most significant risk factor for bladder cancer, and median age at diagnosis is ~70 years. Bladder cancer is more common in men than women (male:female ratio is 3:1), and it is more common in developed countries.
In the majority of cases there is no obvious familial history. However, polymorphisms in two carcinogen-detoxifying genes -N-acetyltransferase 2 (NAT2) and glutathione S-transferase-μ1 (GSTM1) -confer increased risk, and genome-wide association studies have identified single-nucleotide polymorphisms (SNPs) that are associated with moderate risk of bladder cancer with odds ratios of 1.1-1.5. Candidate genes close to these SNPs include MYC; TP63 (which encodes p63); prostate stem cell antigen (PSCA); telomerase reverse transcriptase (TERT)-CLPTM1-like (CLPTM1L); fibroblast growth factor receptor 3 (FGFR3); transforming, acidic coiled-coil containing protein 3 (TACC3); NAT2; chromobox homologue 6 (CBX6); apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3A (APOBEC3A); cyclin E1 (CCNE1) and UDP glucuronosyltransferase 1 family, polypeptide A complex locus (UGT1A).
Environmental risk factors include tobacco smoking, occupational exposure to aromatic amines and polycyclic hydrocarbons, consumption of arsenic-contaminated water, chronic infection with Schistosoma spp., exposure to ionizing radiation and therapeutic abuse of phenacetin-containing analgesics. Tobacco smoking is the major environmental risk factor. It is estimated that >50% of cases of bladder cancer can be attributed to smoking.
Although men are more likely to develop bladder cancer, women often present with more advanced disease and have less favourable prognosis. The reasons for this are not clear.
In Western countries, >90% of cases are urothelial carcinoma. Other histological types include squamous, adenocarcinoma, micropapillary, small cell and plasmacytoid. In regions where the incidence of schistosomiasis is high, squamous cell carcinoma is more common, and bladder cancer may be the cancer of highest incidence.
Most patients present with haematuria, and diagnosis is made following cystoscopy and biopsy. Treatment of non-muscle-invasive bladder cancer (NMIBC) involves transurethral resection. Surgery may be followed by instillation of a chemotherapy agent (for example, mitomycin C), which delays disease recurrence. This is followed by periodic cystoscopy and cytological examination of the urine sediment. Where multiple and/or high-grade tumours or carcinoma in situ (CIS) is detected, a course of Bacillus Calmette-Guerin (BCG) instillation may be used.
Many urine-based tests have been proposed to allow non-invasive follow-up. Many tests show greater sensitivity and specificity for detection of muscle-invasive bladder cancer (MIBC) than NMIBC and, although some are approved for use in the clinic, none have routinely replaced cystoscopic surveillance.
Organ-confined MIBCs are treated by radical cystectomy or radiotherapy. Chemotherapy may be given before or after cystectomy. Five-year survival for patients in this group is ~50%. 50% develop metastatic disease, and median survival is 12-15 months for these patients. Cisplatin-based chemotherapy is used, but 5-year survival is only ~5%.
Because of the need for lifetime surveillance and repeated treatment of recurrent disease, bladder cancer poses a considerable economic burden, and predicted lifetime costs per patient are higher than those for other cancer types. 33 . Both changes are adverse prognostic biomarkers and are found in >50% of MIBC 34 . The best-validated tumour suppressor gene on 9q is TSC1. The TSC1-TSC2 complex negatively regulates the mTOR branch of the PI3K pathway (FIG. 2) . A recent study has also identified mutations in NOTCH1 in 18% of tumours 35 . However, no genes on 9q show biallelic mutational inactivation at frequencies that are compatible with the high frequency of LOH. Indeed, no chromosome 9 genes show significant mutation frequency in exome sequencing studies 11, 17, 36, 37 . This may indicate haploinsufficiency for one or more genes or implicate epigenetic rather than genetic mechanisms of inactivation. After more than 2 decades, the quest to identify drivers of 9q loss in bladder cancer continues.
Other copy number changes and allelic loss in bladder cancer have been identified by comparative genomic hybridization (CGH) and LOH analyses, although many target genes remain unknown [38] [39] [40] . Regions of deletion associated with aggressive disease are 8p, 2q and 5q [41] [42] [43] . In addition to amplicons containing known oncogenes (TABLE 1) , amplicons on 1q21-q24, 3p25, 6p22, 8p12-p11, 11p15, 11q14, 12q24 and 20q12-q13 have been identified by CGH [43] [44] [45] and, apart from homozygous deletion of CDKN2A, homozygous deletion of regions on 9p21.3, 2q36, 11p11, 18p11 and 19q12 have also been reported. Copy number data from low-pass whole-genome sequence and/or single-nucleotide polymorphism (SNP) array analysis of MIBC have also identified amplicons on 19q, 1q22-q23, 8p11 and 20q11, as well as deletions on 2q21, 2q34, 4q22, 5q12, 6p25 and 16p13 (REFS 17,37).
Although MIBCs show many chromosomal rearrangements, the only recurrent gene-gene fusion identified is FGFR3-TACC3 (transforming, acidic coiled-coil-containing protein 3) 37, 46 .
Mutation frequency and signature. Exome sequence from 294 bladder tumours, mostly MIBC or stage T1 tumours, has been reported 11, 17, 36, 37, 47 . Somatic mutation frequency in MIBC is reported as ~300 exonic mutations per sample, with mean and median rates of 7.7 and 5.5 per megabase, respectively 37 ; such a frequency is exceeded only by lung cancer and melanoma, and is dominated by C:G→T:A transitions. A signature of tobacco smoke (polycyclic hydrocarbon) exposure (C:G→A:T transversion) is not apparent. Interestingly, many C:G→T:A mutations are found in the context TpC 48 -a pattern that is characteristic of mutations caused by the APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like) family of cytidine deaminases, which normally restrict the propagation of retroviruses and retrotransposons, and which deaminate cytosine to leave this 'tell-tale' signature 49 . Indeed, APOBEC3B expression is significantly upregulated in human bladder cancer 37, 50 . FGFR alterations. Up to 80% of stage Ta tumours have activating point mutations in FGFR3 (FIG. 3a) , which is associated with favourable outcome [51] [52] [53] [54] [55] [56] [57] . In stage T1 tumours and MIBC, FGFR3 mutation is less common (10-20% in tumours of stage T2 or above) [58] [59] [60] . In cultured normal human urothelial cells (NHUCs), mutant FGFR3 activates the RAS-MAPK pathway and phospholipase Cγ (PLCγ), leading to increased survival and proliferation to high cell density 61 . This in vitro phenotype suggests that FGFR3 mutation could contribute to early clonal expansion within the urothelium in vivo.
FGFR3 is also implicated in contributing to the risk of bladder cancer development. A SNP in an intron of TACC3, which is 70 kb from FGFR3, is associated with bladder cancer risk 62 and with higher risk of recurrence in stage Ta disease, particularly for FGFR3-mutant NMIBC. The mechanism (or mechanisms) underlying these links is not clear, but one possibility is that altered chromatin structure associated with increased expression of FGFR3 could increase the probability of mutation and/or increase the expression and impact of mutated proteins.
In normal urothelium, FGFR3 is expressed as the IIIb isoform, which mainly binds to FGF1. A splice variant (Δ8-10) encodes a secreted form that lacks the transmembrane domain, which may act as a negative regulator by sequestering FGFs or by binding to fulllength receptors 63 . In bladder cancer cell lines, reduced expression of full-length FGFR3-IIIb and FGFR3-Δ8-10 isoforms, and a switch to the FGFR3-IIIc isoform (which binds to many FGF ligands 64 ) may facilitate autocrine or paracrine signalling 63 . Furthermore, many bladder cancers, including those without FGFR3 point mutations, show increased expression of FGFR3 (REF. 60 ). The microRNAs (mi RNAs) miR-99a and miR-100, which negatively regulate the expression of FGFR3, are also commonly downregulated in bladder cancer, particularly in NMIBC 65 . Approximately 5% of cell lines and tumours contain chromosomal translocations that generate FGFR3 fusion proteins. These fusion proteins comprise amino acids 1-760 of FGFR3 (IIIb isoform, including the kinase domain) fused in-frame to TACC3 (REFS 17, 37, 46) or BAI1-associated protein 2-like 1 (BAIAP2L1) 46 . These are highly activated and transforming oncoproteins. An additional mechanism for the activation of FGFR3 in bladder cancer could include upregulated expression of FGF ligands by tumour cells or the stroma, although this has not been adequately assessed (FIG. 3b) .
FGFR1 expression is upregulated in both NMIBC and MIBC 66 , although no mutations have been reported. An increased ratio of the FGFR1β:FGFR1α CCND1, cyclin D1; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; NI, no information; RXRA, retinoid X receptor-α. *Genes identified as significantly mutated in >5% of cases in the largest exome and whole-genome sequencing study reported so far 37 .
splice variants is found in tumours of higher grade and stage 66 . The β-isoform, which lacks the first extracellular immunoglobulin-like domain, shows increased sensitivity to FGF1 (REF. 67) (FIG. 3b) . FGF2 stimulation of FGFR1β in NHUCs activates the MAPK pathway and PLCγ, leading to increased proliferation and reduced apoptosis 66 . Similar stimulation in bladder cancerderived cell lines induced an epithelial-mesenchymal transition (EMT), a major feature of which is PLCγ-mediated upregulation of the cyclo oxygenase COX2 (also known as PTGS2) 68 . Consistent with this, bladder cancer cell lines with the highest FGFR1 expression show a mesenchymal phenotype (indicated by low E-cadherin expression) and upregulated FGF2 expression, and those with epithelial phenotype show higher FGFR3 and E-cadherin expression 69 . PI3K pathway alterations. The PI3K pathway is activated by several mechanisms (FIG. 2) . Some events are not mutually exclusive, implying non-redundant or non-canonical functions in bladder cancer 24 . Upstream activators include ERBB receptors. ERBB3 interacts with p110α, the catalytic subunit of PI3K, and conveys signals from ERBB2-ERBB3 heterodimers. Epidermal growth factor receptor (EGFR; also known as ERBB1) induces PI3K activation via RAS activation. Overexpression of EGFR, ERBB2 and/or ERBB3 in subsets of bladder cancer is associated with grade, stage and outcome [70] [71] [72] [73] , and ERBB2 and ERBB3 are mutated in some MIBCs 36, 37 . ERBB2 amplification or overexpression is more common in metastases than in the corresponding primary tumour, implying a role in the metastatic process 74 . Activation of the receptor tyrosine kinases, MET and RON (also known as MST1R), also activates the PI3K pathway, and they are upregulated in aggressive bladder cancer [75] [76] [77] . It is not yet clear whether FGFR3 is a major activator of the PI3K pathway. Although mutant FGFR3 does not activate the pathway in NHUCs 61 , higher levels of phosphorylated AKT (which indicates that it is activated) have been reported in FGFR3-mutant tumours than in tumours with wild-type FGFR3 (REF. 78 ).
Activating mutations of PIK3CA (which encodes p110α) occur more commonly in the helical domain (E545K and E542K) than in the kinase domain (H1047R) and are found in ~25% of NMIBCs and less frequently in MIBCs 24, 25, [78] [79] [80] . p110α-E542K and p110α-E545K require interaction with RAS-GTP but not binding to the PI3K regulatory subunit p85 for activity, whereas p110α-H1047R activity depends on p85 binding but not on RAS-GTP binding 81 . p110α proteins with mutations in the helical domain possibly cooperate with events that activate RAS in bladder cancer. The expression of mutant PIK3CA confers a proliferative advantage at confluence and stimulates intraepithelial movement in NHUCs, and helical domain mutants show higher levels of activity 82 . The lipid and protein phosphatase PTEN negatively regulates PI3K. PTEN commonly shows LOH in MIBC [83] [84] [85] , but biallelic inactivation is uncommon. Overall, 46% of bladder cancer cell lines (mostly derived from MIBC) had PTEN alterations 24 . Downregulated expression of PTEN in MIBC is associated with TP53 (which encodes human p53) alteration and poor outcome 24, 86 . Consistent with this, urothelial Trp53 (which encodes mouse p53) and Pten dual deletion, but not deletion of either gene alone, leads to the development of metastatic bladder cancer in mice 86 . The protein phosphatase activity of PTEN influences cell motility. PTEN-G129E, a mutant that is deficient in lipid but not protein phosphatase activity, inhibits the invasive phenotype of the PTEN-mutant T24 bladder cancer cell line 87 , which implies a more important role for PTEN protein phosphatase activity in invasive bladder cancer. This is consistent with the finding that only PIK3CA mutation, which is predicted to phenocopy loss of PTEN lipid phosphatase activity, occurs in NMIBC.
Other pathway alterations include TSC1 mutation (discussed above) and several mutations reported at low frequency (TABLES 1,2).
Activation of the MAPK pathway. The role of MAPK signalling (FIG. 2) and its relationship to key mutations in bladder tumours are not clear. RAS (HRAS or KRAS) and FGFR3 mutations are mutually exclusive in bladder cancer. Mutation of one or the other in >82% of NMIBC 88 may suggest that RAS and FGFR3 share a similar function. However, it is likely that there are also non-redundant functions, as RAS mutation is relatively infrequent compared with FGFR3 mutation and, unlike FGFR3 mutation, RAS mutation occurs at similar frequencies in NMIBC and MIBC. Although mutant FGFR3 activates MAPK pathway but not PI3K pathway signalling in NHUCs 61 , immunohistochemistry for phosphorylated ERK (an indicator of MAPK pathway activation) does not show a strong relationship with FGFR3 mutation or expression in tumour tissues 78, 89 , and at least some bladder cancer cell lines are less sensitive to MEK inhibitors than NHUCs 90 . Although the finding that both FGFR3 mutation and PIK3CA mutation commonly co-occur in NMIBC 78, 80 suggests cooperative activation of MAPK and PI3K pathways, the exact role of FGFR3 in activation of the MAPK pathway requires further clarification. The recent finding of inactivating mutations in NOTCH pathway genes implicates this pathway in >40% of bladder cancers 35 , suggesting that the pathway has a tumour suppressor role in this cellular context. Higher levels of phosphorylated ERK1 and ERK2 were found in tumours with NOTCH pathway alterations than in FGFR3-or RAS-mutant tumours. This was mediated via reduced expression of several dual-specificity protein phosphatases (DUSPs) that target phosphorylated ERK, which are regulated by the intracellular domain of NOTCH1 (N1ic). Exogenous expression of N1ic or the ligand Jagged 1 (JAG1) in bladder cancer cells reduced phosphorylated ERK levels and inhibited proliferation. Overall, current data suggest that the majority of bladder cancers may be highly dependent on ERK.
Hedgehog and WNT signalling. Several components of the canonical WNT signalling pathway are altered in bladder cancer. Low frequencies of mutation in adenomatous polyposis coli (APC) and CTNNB1 (which encodes β-catenin) have been reported, and reduced expression or increased nuclear localization of β-catenin is frequent in MIBC 25, [91] [92] [93] [94] . Epigenetic silencing of the WNT antagonists, secreted frizzled receptor proteins (SFRPs) 95 and WNT inhibitory factor 1 (WIF1) 96 , has also been reported. The importance of WNT signalling is confirmed in mouse models. Expression of activated β-catenin in suprabasal urothelial cells in conjunction with Pten deletion led to bladder cancer development. Correlation between nuclear β-catenin, reduced PTEN expression and increased levels of phosphorylated AKT in human bladder cancer indicates that there is likely to be cooperation between WNT and PI3K signalling 97 . Another study that expressed active β-catenin in urothelial basal cells reported development of papillary tumours, which are found more commonly in male mice. Synergy between β-catenin and androgen receptor signalling was demonstrated, which implicates these factors in the observed sexual dimorphism of bladder cancer 98 . In mice, cooperation between β-catenin and mutant Hras is also reported, with MAPK pathway signalling rather than PI3K pathway signalling activated in the resulting tumours 99 . It will be important to examine whether such cooperation exists in human bladder cancer, and the relationship to gender.
The importance of hedgehog signalling in MIBC development has been demonstrated in mouse models and human bladder cancer [100] [101] [102] . In mice, urothelial regeneration following injury is driven by sonic hedgehog (SHH)-expressing basal cells, which elicit secretion of factors, including the transcription factor GLI1 and WNT pathway proteins by stromal cells, which in turn stimulate proliferation and differentiation of urothelial cells 100 . These cells were also the progenitors of MIBC in the N-butyl-N-4-hydroxybutyl nitrosamine (BBN)-induced urothelial cancer model 101 . Although these progenitor cells and normal human urothelium express SHH, expression is lost in BBN-MIBC in mice and in human MIBC cell lines 103 and tissues 102 . Dissection of BBN-induced tumorigenesis has revealed that loss of hedgehog signalling blocks production of stromal factors that induce urothelial differentiation, including bone morphogenetic protein 4 (BMP4) and BMP5, suggesting that CIS progression to MIBC is triggered by loss of hedgehog signalling. Importantly, tumour progression could be blocked by pharmacological activation of the BMP pathway, suggesting a possible therapeutic approach for human NMIBC 102 . Notably, SHH, BMP4 and BMP5 were shown to be significantly downregulated in mRNA sequencing data from The Cancer Genome Atlas (TCGA) study of MIBC, particularly in the aggressive 'basal' subtype 102 .
Cell cycle regulation. Almost every MIBC has defects in genes encoding proteins that control the G1 cell cycle checkpoint. Inactivation of TP53, RB1 and CDKN2A is common (TABLE 2) and has adverse prognostic importance 104 . Taken together with amplification or overexpression of MDM2, p53 function was predicted to be inactivated in 76% of MIBCs 37 . Similarly, RB1 loss is common, and amplification and overexpression of E2F3, which is normally repressed by RB1, is associated with RB1 or p16 loss in MIBC 105 . Cyclin D1 (CCND1) and CCND3 are implicated in NMIBC. CCND1 (11q13) is amplified in ~ 20% of bladder cancers 106 . High nuclear expression in 33% of stage Ta and T1 tumours was associated with higher proliferative index and reduced disease-free survival. High expression of CCND3 (in 13% of NMIBCs) was also associated with reduced survival 107 . Upregulated expression of these cyclins may represent a more specific mechanism of inactivation of the G1 checkpoint in NMIBC.
Epigenetic alterations: chromatin modifiers at centre stage. Extensive DNA methylation changes have been reported in bladder cancer, and many of these show clinicopathological associations [108] [109] [110] [111] [112] [113] [114] [115] [116] . A major subtype of MIBC has been identified that has high-level promoter hypermethylation associated with smoking pack-years 37 . Comparisons of NMIBC and MIBC reveal distinct patterns of hypomethylation in non-CpG islands in NMIBC and widespread CpG island hypermethylation in MIBC 114, 115 . Whereas hypermethylation in promoters is linked to gene silencing, hypomethylation within gene bodies is usually associated with upregulated expression 116 . In medulloblastoma, such regions of hypomethylation are marked by histone H3 lysine 4 (H3K4) trimethylation, a marker of open chromatin 117 . Genome-wide analysis of methylation and repressive histone marks in bladder cancer also indicates the importance of both DNA methylation and histone methy lation in gene silencing 118 . Genomic regions showing DNA copy number-independent transcriptional deregulation were found to be associated with H3K9 and H3K27 methylation and H3K9 hypoacetylation rather than with DNA methylation, and this pattern was related to a CIS-associated expression signature 119 . Genome sequencing has identified mutations in chromatin regulators that occur at higher frequency in MIBC than in other epithelial cancers 11, 17, 36, 37 (TABLE 2) .
89% of MIBCs had a mutation in one or more chromatin-regulating genes 37 . Frequently mutated genes include lysine-specific demethylase 6A (KDM6A, which encodes a histone demethylase), mixed-lineage leukaemia 2 (MLL2; also known as KMT2D, which encodes a histone methyltransferase) and AT-rich interactive domain 1A (ARID1A, which encodes a component of the SWI/SNF chromatin-remodelling complex). KDM6A demethylates H3K27, leading to a more open chromatin configuration. MLL2 methylates H3K4, which also favours euchromatin formation and suggests transcriptional activation. Thus, loss of function of these genes is predicted to lead to gene silencing. Other genes involved in chromatin modification that are mutated in >5% of MIBC samples include the following: MLL (also known as KMT2A) and MLL3 (also known as KMT2C), which encode histone methyltransferases; E1A-binding protein p300 (EP300) and CREB-binding protein (CREBBP), which encode histone acetyltransferases; nuclear receptor co-repressor 1 (NCOR1), which encodes a histone deacetylase; CHD6 and CHD7, which encode chromodomain helicase DNA-binding proteins; and a CREBBP activator, Snf2-related CREBBP activator protein (SRCAP) 17, 36 . The predominance of inactivating mutations implicates these as tumour suppressor genes. Although several genes are mutated at low frequency, they may be functionally redundant, which potentially reduces complexity to fewer phenotypic subgroups. For example, mutations in KDM6A and MLL2 were reported to be mutually exclusive 37 .
Molecular biomarkers
A detailed discussion of prognostic biomarkers is beyond the scope of this Review. However, the application of molecular biomarkers for non-invasive monitoring of NMIBC is approaching clinical applicability and merits brief discussion here. As NMIBCs are poorly detected by urine cytology, analysis of FGFR3 mutation combined with other DNA-based biomarkers provides a useful test for disease monitoring [120] [121] [122] . Many studies report detection of bladder cancer by analysis of methylation biomarkers in urine. Examples include several panels of biomarkers that are used alone 114, [123] [124] [125] or in combination with FGFR3 mutation 126 . The most common event described in bladder cancer so far is point mutation of the telomerase reverse transcriptase (TERT) promoter in ~80% of tumours, regardless of grade and stage. Mutations are mainly at positions -124 bp and -146 bp relative to the transcriptional start site, and such a finding allows development of specific assays that are suitable for detection in urine 127, 128 . Undoubtedly, when used in combination with other urine biomarkers, this will improve sensitivity for the detection of bladder cancer.
Pathogenesis
Cell of origin. The normal human urothelium comprises a layer of basal cells that are in contact with the basement membrane, several layers of intermediate cells and a single layer of large, superficial 'umbrella' cells with a specialized apical membrane to accommodate bladder expansion and contraction 129 . Lineage-tracing studies in mice using SHH-Cre have identified SHH + basal cells that can repopulate the entire urothelium following injury 100 . Whether this is the case in humans is unknown, but the presence of large monoclonal areas (up to 4.7 mm in diameter) within the urothelium that comprise basal, Figure 2 | The PI3K and MAPK pathways in bladder cancer. Growth factor-mediated signalling or mutational activation of both PI3K and MAPK pathways is common in bladder cancer. Receptor tyrosine kinases (RTKs), epidermal growth factor receptor (EGFR), ERBB2, ERBB3, fibroblast growth factor receptor 1 (FGFR1) and FGFR3 may be activated by ligand, overexpression and/or mutation in bladder cancer. Through adaptor proteins, these RTKs activate RAS. Signalling via the RAS-RAF-MEK-ERK cascade leads to phosphorylation of many substrates that can have multiple cellular effects depending on the intensity and duration of signalling. In many situations proliferation is induced. Activated RTKs bind to p85 (the regulatory subunit of PI3K) and recruit the enzyme to the membrane, where it phosphorylates phosphatidyinositol-4,5-bisphosphate (PIP2) to generate PIP3. Activated RAS can also directly activate PI3K. PIP3 recruits 3-phosphoinositide-dependent protein kinase 1 (PDK1; also known as PDPK1) and AKT, resulting in activation of AKT by phosphorylation, which leads to both positive and negative regulation of a wide range of target proteins (not all shown). Cyclin D1 (CCND1) and MDM2 are upregulated directly or indirectly, resulting in a positive stimulus via the RB or p53 pathways, respectively. AKT also phosphorylates and inactivates tuberous sclerosis 2 (TSC2), leading to activation of mTOR complex 1 (mTORC1), which controls protein synthesis. TSC1 forms an active complex with TSC2, and loss of function of either protein leads to dysregulated mTOR signalling. AKT phosphorylates and inactivates glycogen synthase kinase 3β (GSK3β), relieving its suppression of β-catenin, which is freed to enter the nucleus and activate gene expression. MYC expression is induced as a consequence of both ERK and AKT signalling. Key genes that are activated in bladder cancer are shown in dark red and those that are inactivated in green. BAD, BCL-2-associated agonist of cell death; FOXO, forkhead box O; RHEB, Ras homologue enriched in brain. 101 . Recent evidence suggests that such cancer stem cells may contribute to therapeutic resistance by repopulating residual tumours between chemotherapy cycles 135 .
In humans, there is evidence for non-basal tumourinitiating cells in more-differentiated bladder cancers. Marker combinations corresponding to different urothelial differentiation states could stratify bladder cancer into clinically relevant subgroups, and tumours with the least differentiated (basal) tumour-initiating cells had the worst outcome 136 . Similar evidence was reported from a lineagetracing study in mice, in which cells in the intermediate layer were implicated as the cell of origin for BBN-induced papillary tumours 137 . Diversity in cancer stem cell phenotype may contribute to the divergent development of NMIBC and MIBC and, in turn, define the genomic events that subsequently participate in tumour development.
Molecular features of pre-neoplastic urothelium.
Chromosome 9 LOH is found in 'normal' urothelium and hyperplasia in patients with NMIBC [138] [139] [140] [141] , and at higher frequency than FGFR3 mutation in flat hyperplasia, implying that chromosome 9 loss is an earlier event than FGFR3 mutation 142 . Dysplasia and CIS are considered precursors of MIBC and show chromosome 9 LOH, TP53 mutation [143] [144] [145] and multiple other chromosomal alterations 146 . No FGFR3 mutations have been reported in CIS 147 . In morphologically 'normal' or dysplastic urothelium adjacent to MIBC, alterations found in the tumour are present, indicating spread of cells from the tumour or tumour development within a field of altered urothelium [148] [149] [150] [151] . Detailed mapping of entire cystectomy specimens reveals that, in the absence of detectable morphological abnormality, large macroscopically 'normal' urothelial patches show LOH of specific chromosomal regions. Areas of mild, moderate or severe dysplasia show complex patterns of LOH, suggesting that there are sequential evolutionary 'waves' of change associated with the acquisition of growth advantage. Thus, it is envisaged that the development of MIBC involves clonal expansion, within which subclones with additional alterations arise (FIG. 4) . Six critical regions of LOH were identified, and biallelic inactivation of integral membrane protein 2B (ITM2B) and lysophosphatidic acid receptor 6 (LPAR6; also known as P2RY5) was demonstrated in one of those regions 150, 152 .
Multifocality, clonality and chronology of events during urothelial carcinoma pathogenesis. The development of multiple bladder cancers in the same patient is common, and this enables examination of clonality and molecular evolution. Two concepts have been proposed to explain the origin of multifocal bladder cancer. As a result of extensive carcinogenic insults, many cells may become altered and give rise to independent tumours. Alternatively, a single clone may spread via intra epithelial migration or implantation. Although a few patients develop more than one apparently independent tumour (that is, oligoclonal disease) 153 , tumours from the same patient are commonly related 154 , and there is evidence for subclonal genomic evolution, sometimes complex, in different lesions (reviewed in REF. 155 ). Loss of the same allele on chromosome 9 in all related tumours again indicates that this is an early event [156] [157] [158] 157, 159, 160 , which provides an explanation for the observation that recurrent tumours may be of lower grade than preceding tumours 161 . These observations provide further evidence for widespread 'field change' in the diseased bladder. The molecular complexity of related tumours suggests that considerable intratumoural heterogeneity may be a feature of individual bladder cancers, although this has not yet been systematically investigated. Analyses so far on bulk tumour samples may not reveal such heterogeneity. Deep sequencing should now allow such complexity and phylogeny to be examined in more detail. The primary tumour has developed within a large area of urothelium of normal appearance containing molecular alteration 'c'. Within this 'field' of change a dysplastic area (which also has normal appearance at cystoscopy) represents a subclone with 'c+d' alterations; within this dysplastic area, a patch of CIS representing the immediate precursor to the overt tumour ('c+d+e+f') is recognized as an inflamed patch ('c+d+e'). A second tumour and CIS resected at a later date have also developed within the large altered field containing alteration 'c' but differ in all other alterations (g, h and i). The possibility that tumours with independent initiating events may develop in some patients is indicated by patches 'a' and 'b', both of which may remain morphologically silent for many years. The dotted line indicates a urothelial patch as described by Gaisa et al. 124 , which is putatively derived from a single stem cell. Despite independent tumour-initiating events, cells with alterations 'a' and 'b' are clonally related. The presence of large and clinically silent areas of pre-neoplastic urothelium emphasizes the need for novel approaches for local therapeutic targeting.
EMT and metastasis. EMT is a reversible process that involves changes in cell morphology, differentiation and motility, facilitating invasion and metastasis. Markers of EMT -loss of expression of E-cadherin and tight-junction proteins, and upregulation of vimentin and fibronectin -are associated with MIBC, resistance to therapeutic agents and poor outcome.
EMT is mediated by zinc-finger E-box binding homeobox 1 (ZEB1), ZEB2, TWIST, SNAIL (also known as SNAI1) and SLUG (also known as SNAI2), which transcriptionally repress epithelial markers. ZEB1 and ZEB2 are regulated by members of the miR-200 family and miR-205 (REF. 162 ). miR-200 is downregulated in bladder cancer cell lines with mesenchymal phenotype, and epigenetic silencing is reported in MIBC 163 . These mi RNAs also regulate ERBB receptor feedback inhibitor 1 (ERRFI1), and their silencing confers resistance to EGFR in mesenchymal bladder cancer cells that can be reversed by the expression of miR-200 (REF. 164 ).
FGFR1 signalling and subsequent COX2 upregulation can induce EMT in bladder cancer cells 68 (discussed above). In an animal model of bladder cancer metastasis using an FGFR1-dependent cell line, FGFR inhibition reduced the development of circulating tumour cells and metastasis but not primary tumour growth 69 . Interestingly, although FGFR2 shows reduced expression in MIBC 165 , cells selected for enhanced metastatic capability were found to be dependent on FGFR2 isoform IIIc for this phenotype, which was associated with a mesenchymalepithelial transition 166 . Thus, FGFRs are implicated both in the EMT required early in the process of metastasis and in the mesenchymal-epithelial transition required to recapitulate the epithelial phenotype at the metastatic site.
Other factors implicated in bladder cancer cell EMT include the transcription factor inhibitor of DNA binding 1 (ID1) 167 and the long non-coding RNA (lncRNA) H19 (which is upregulated in MIBC). H19 promotes WNT-β-catenin activation via association with enhancer of zeste homologue 2 (EZH2) and subsequent downregulation of E-cadherin 168 . Similarly, the lncRNA metastasisassociated lung adenocarcinoma transcript 1 (MALAT1), which is upregulated by transforming growth factor-β (TGFβ) in bladder cancer cells, induces EMT 169 . TP63 (which encodes p63) is expressed in the basal and intermediate cell layers of the normal urothelium. Studies of TP63 isoforms show that ΔNp63 expression is linked to EMT in tumours 170 , and this is associated with a more 'basal' phenotype with adverse prognosis [170] [171] [172] . Recent expression profiling of large numbers of MIBC samples defines a claudin-low basal subtype (discussed below) that is characterized by the enrichment of EMT markers and the expression of low levels of cytokeratins 37, 173 . Metastasis of NMIBC is rare, but half of all MIBCs metastasize. Cisplatin-based neoadjuvant chemotherapy before cystectomy confers a small survival benefit, and this is thought to be due to the elimination of occult metastases, but survival is poor and improved therapeutic approaches are urgently needed. In addition to genes involved in EMT, preclinical studies suggest that RHO-GDP dissociation inhibitor 2 (RHOGDI2), the activity of which is regulated by SRC, is a metastasis suppressor in MIBC 174, 175 . In contrast to most tumour types, the expression and activation of SRC is highest in NMIBC [175] [176] [177] , which is consistent with the activity of RHOGDI2 in these tumours. Further work on the consequences of loss of RHOGDI2 expression implicated endothelin 1 (EDN1) and versican (VCAN) as promoters of an inflammatory environment that involves macrophages and the chemokine (C-C motif) ligand 2 (CCL2)-chemokine (C-C motif) receptor 2 (CCR2) signalling axis that is permissive for metastasis 178, 179 . A similar relationship has been reported between loss of SPARC (secreted protein, acidic, cysteine-rich) and metastasis and regulation of inflammatory response in bladder cancer 180 . Reduced expression of activating transcription factor 3 (ATF3), which is also a regulator of inflammation, has been implicated in driving metastasis through transcriptional regulation of gelsolinmediated actin remodelling. Both SPARC and ATF3 are downregulated in MIBC, and ATF3 was shown to reduce metastasis in an in vivo experimental model 181 . The RAL GTPases RALA and RALB have also been implicated in bladder cancer metastasis 182, 183 . CD24 -a RAL GTPaseregulated glycosyl phosphatidylinositol (GPI)-linked sialoglycoprotein -is required for metastatic bladder cancer colonization in mice and shows increased expression in human bladder cancer metastases 184 . Interestingly, prognostic value seems to be confined to male patients; in Cd24-null mice, reduced carcinogen-induced tumour incidence was seen only in males 185 . As CD24 is androgenresponsive, if these data are confirmed, then androgen ablation could have therapeutic impact in males 185 .
Beyond the two-pathway model
The two tumour groupings that have dominated the literature on bladder cancer cannot provide an explanation for the considerable heterogeneity in clinical behaviour. The two-pathway model has been expanded in FIG. 5 to include potential pathogenic links that are suggested by molecular data and the possibility of multiple molecular routes to each recognized disease state. Previous gene expression profiling studies have reported signatures associated with stage, grade and outcome [186] [187] [188] [189] [190] [191] . Recent studies now begin to unravel the heterogeneity in clinical behaviour, revealing multiple molecular subtypes that traverse grade and stage groupings.
An mRNA expression analysis of bladder cancers of all grades and stages by Sjödahl et al. identified five major subtypes termed urobasal A (UroA), UroB, genomically unstable (GU), squamous cell carcinoma-like (SCCL) and 'infiltrated' (which is highly infiltrated with non-tumour cells) 192 (FIG. 6) . Subsequently, it was suggested that the SCCL group should be termed 'basal' , as it shares features with basal-type breast cancers 193 . UroA and UroB tumours express FGFR3, CCND1 and p63; GU tumours express low levels of these proteins but high levels of ERBB2 and E-cadherin; and SCCL (or basal) tumours express EGFR, P-cadherin, KRT5, KRT6, KRT14 and proteins involved in keratinization. UroA tumours showed good prognosis; GU and infiltrated bladder cancers showed intermediate prognosis; and SCCL (or basal) and UroB tumours had the worst prognosis. Although UroB tumours have TP53 mutation and many were MIBCs, they show epithelial Nature Reviews | Cancer characteristics, including FGFR3 mutation, which may indicate evolution from UroA tumours. UroB tumours also show homozygous deletion of CDKN2A, which could be a mechanism by which FGFR3-mutant NMIBCs progress 31 (discussed above). Three subsequent studies of MIBC have defined transcriptional subtypes 37, 173, 194 with considerable overlap 195 . There are two major 'basal' and 'luminal' subtypes that show similarities to intrinsic breast cancer subtypes (FIG. 6) . Luminal MIBCs are enriched for uroplakins, KRT20, ERBB2 and differentiation markers such as forkhead box A1 (FOXA1; also known as HNF3α), GATA-binding protein 3 (GATA3), tripartite motif-containing protein 24 (TRIM24) and peroxisome proliferator-activated receptor-γ (PPARγ), and these frequently have papillary morphology and FGFR3 upregulation and/or mutation. A TCGA study defined four expression clusters (I-IV), one of which (Cluster I) expressed luminal markers 37 . Choi et al. 194 described a luminal subtype termed 'p53-like' with an activated wild-type p53 signature, low levels of cell cycle and proliferation markers, and enrichment of myofibroblast and extracellular matrix markers, perhaps reflecting stromal and fibroblast infiltration 195 . The infiltrated subgroup of Sjödahl et al. 192 mostly overlapped with this p53-like subgroup. Tumours in TCGA Cluster II shared features with luminal and p53-like subtypes, and some basal and luminal tumours described by Damrauer et al. 173 also exhibited characteristics of the p53-like subgroup. Tumours expressing basal markers (KRT5, KRT6, KRT14, CD44 and CDH3) were present in all three studies. Two studies identified claudin-low basal tumours expressing markers that are characteristic of EMT and that have low levels of cytokeratins, which is analogous to some breast cancers 37, 173 . Some infiltrated tumours also showed overlap with this subgroup. In all studies, the SCCL (or basal) MIBCs showed the worst prognosis, and those with papillary architecture and high expression levels of FGFR3, E-cadherin, GATA3, FOXA1 and uroplakins had the best prognosis (FIG. 6) . Bioinformatics analyses implicated transcription factors that are active in the basal or stem cell compartment of the normal urothelium -signal transducer and activator of transcription 3 (STAT3), nuclear factor-κΒ (NF-κB), hypoxia-inducible factor 1 (HIF1) and p63 -as potential regulators in basal tumours, and PPARγ and oestrogen receptor pathways were implicated in luminal tumours 194 . A recent pan-cancer molecular classification also defined a squamous subtype that contains four different tumour types, including a subset of TCGA MIBC samples that show worse overall survival than other bladder cancers 196 . Network analysis revealed significant TP63 expression that was associated with a high level of expression of the oncogenic ΔNp63 isoform. It is likely that SCCL (or basal) MIBCs expressing this isoform represent the lethal subset of p63-expressing advanced Figure 5 | Potential pathways of urothelial carcinoma pathogenesis. Potential pathogenesis pathways are shown based on histopathological and molecular observations. The blue and purple pathways indicate the two major pathways with distinct histopathological and molecular features that have been recognized for the past two decades. Percentages at diagnosis and key molecular features are indicated. The recent identification of multiple distinct molecular subtypes of non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) suggests multiple subpathways within each of the major pathways. It should be noted that the existence of multiple subtypes within all of the histologically recognizable intermediates remains hypothetical. Development of histopathologically recognizable urothelial alterations is preceded by clonal expansion of altered cells within the urothelium. Low-grade papillary tumours may arise via simple hyperplasia and minimal dysplasia, and these are characterized at the molecular level by loss of heterozygosity (LOH) of chromosome 9 and activating mutations of fibroblast growth factor receptor 3 (FGFR3), PIK3CA (which encodes p110α of PI3K) and stromal antigen 2 (STAG2). These non-invasive tumours recur frequently but are genetically stable. Invasive carcinoma is thought to arise via flat dysplasia and carcinoma in situ (CIS), which commonly show TP53 mutation in addition to chromosome 9 deletions but no FGFR3 mutations. Invasive tumours are genetically unstable and accumulate many genomic alterations. Uncertainty about the possible development of high-grade non-invasive papillary tumours from flat dysplasia is indicated by a dashed arrow. The finding of a subtype of invasive carcinomas with FGFR3 mutation and loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) may suggest a route by which low-grade non-invasive papillary tumours can progress to muscle invasion (dashed arrow). ARID1A, AT-rich interactive domain 1A; EMT, epithelial-mesenchymal transition; RHOGDI1, RHO-GDP dissociation inhibitor 2; ZEB1, zinc-finger E-box binding homeobox 1. bladder cancers that were reported by others 170 . The relevance of p63 expression in UroB tumours with poor prognosis remains unresolved, but the expression of different p63 isoforms in NMIBC and MIBC may account for this 170 . It is currently unclear whether analyses that have assessed only MIBC have revealed all biologically relevant hetero geneity, as some data suggest that transcriptional subtypes are independent of conventional grade and stage groupings 192 . There is an ongoing debate on how to integrate and explore this complexity 197, 198 . Recent studies also indicate potential predictive value. Activation of the EGFR pathway has been identified in basal-type MIBC, and it was shown that cell lines with this signature were sensitive to EGFR inhibition 199 . Additionally, the p53-like subgroup of Choi et al. 194 contained tumours that were resistant to cisplatin-based chemotherapy, and it was confirmed in independent samples and in bladder cancer cell lines that this signature had predictive value. Although the signature did not identify all resistant tumours because half of the basal-type tumours were also resistant, this represents an important step towards more rational selection of therapy.
Further work will be needed to generate consensus classifiers and robust assays that are suitable for clinical implementation. A simple classifier based on two histology variables (grade and urothelial differentiation pattern) and the expression of two proteins (KRT5 and CCNB1) has been reported, which reproduced an original genomewide expression classification 192 with an accuracy of 0.88 (REF. 193) . A notable finding was that UroA and UroB tumours retain expression pattern and histology that are reminiscent of the normal urothelium, with expression of several markers, including proliferative biomarkers, in basal cells only, which implies retention of dependence on stromal interactions. SCCL (or basal) tumours had lost this pattern and showed CDH3, KRT5 and EGFR at higher level throughout the tumour parenchyma. This subtype showed a keratin expression profile (KRT14 + KRT5 + KRT20 − ) that characterizes the least differentiated class of tumour-initiating cells described by Chan et al. 134 and the class termed basal in the study of Volkmer et al.
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. DNA-based genome-wide analyses also indicate the existence of multiple subclasses of bladder cancer. Analysis of DNA copy number and mutation status has identified multiple genomic subtypes of tumours within the conventional grade and stage groupings 43 , and MIBCs have been subdivided into three major groups according to copy number alterations and mutation status 37, 43 . The latter groups separate tumours with frequent TP53 mutation from those with FGFR3 mutation and CDKN2A loss, and define a group with an increased frequency of focal amplification and mutations in MLL2 (REF. 37 ). DNA methylation profiles also identify bladder cancer subtypes 37, 115, 116, 200 . Four "epitypes" (REF. 116 ) showed broad alignment with previously defined expression subtypes 192, 201 . A key feature of these epitypes was differential expression of homeobox (HOX) genes. Repression of several HOX genes that are also repressed in pluripotent cells was found in the most aggressive epitype (type D).
A major goal is to integrate information from all platforms to provide the best prognostic and predictive biomarkers for clinical application. As DNA and mi RNAs are more robust molecules than mRNA in formalinfixed paraffin-embedded (FFPE) specimens, a combination of these and protein biomarkers may ultimately provide the most useful classifiers.
Conclusions and future perspectives For many years, molecular understanding of bladder cancer biology has lagged behind that of other solid cancers, and this has represented a major barrier to improving clinical care. Although the long-described disease subtypes (NMIBC and MIBC) are clearly distinct at the molecular level, this has not provided adequate prognostic or predictive information for clinical application. With the advent of large-scale genome-wide profiling studies, the field is now poised to replace the conventional two-pathway model of bladder cancer pathogenesis with a more complex and molecularly credible description of disease pathogenesis and clinical behaviour and to meet the clinical needs of patients in a more personalized way.
Although non-invasive disease is not life-threatening, its recurrent nature makes this more expensive to treat than other cancers, and disease monitoring and treatment are associated with considerable morbidity. Key biomarker panels already hold potential for application in non-invasive urine-based monitoring. A remaining challenge is to develop therapies that can better treat localized disease. Knowledge of the widespread fields of altered cells present in many patients argues for early therapeutic intervention and enhanced efforts to clarify the common and targetable early events in NMIBC. Few NMIBCs have been studied by exome or whole-genome sequencing, and it will be important to establish detailed mutation profiles for this important patient population.
For MIBC, molecular profiling in the context of large clinical trials is required to confirm the ability of molecular signatures to stratify patients before treatment with conventional chemotherapy. For these patients, recent insights should also guide the design of new clinical trials, with many possibilities for therapy with targeted agents. The striking finding of frequent somatic mutation of epigenetic modifiers in bladder cancer may offer completely new treatment avenues, where the potential reversibility of phenotype may hold promise for the treatment of some tumour subtypes. Stage T1 tumours are a particularly difficult group to manage. Progression to invasion is relatively common, but there is a major debate on whether to remove or preserve the bladder. Evidence from studies that include some T1 tumours indicates that, as for MIBC, these may be subclassified to provide objective guidance for treatment. Large collaborative studies are now needed to allow identification of robust prognostic biomarkers and, for all subtypes, robust diagnostic assays are needed.
